{"title":"egfr突变的肺腺癌患者接受吉非替尼治疗时的类固醇相关性肺气肿性膀胱炎","authors":"Diego Marquez-Medina , Sanjay Popat","doi":"10.1016/j.ctrc.2015.06.003","DOIUrl":null,"url":null,"abstract":"<div><p>Advanced non-small cell lung cancer (NSCLC), the most lethal malignancy worldwide, obtains a small long-term benefit from chemotherapy. However, 16% of Caucasian patients presenting sensitizing mutations in the epidermal growth factor receptor have a high sensitivity to the tyrosine kinase inhibitor gefitinib. Gefitinib is a safe drug, with mild diarrhea, emesis, or skin rash the most common toxicities. However, rare adverse events such as <em>pneumatosis intestinalis</em> have been communicated. We first report a very rare case of emphysematous cystitis in a female patient with <em>EGFR</em>-mutant lung adenocarcinoma while on gefitinib treatment, taken advance to review risk factors for this infectious complication.</p></div>","PeriodicalId":90461,"journal":{"name":"Cancer treatment communications","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.ctrc.2015.06.003","citationCount":"0","resultStr":"{\"title\":\"Steroid-related emphysematous cystitis in an EGFR-mutant patient with lung adenocarcinoma while on gefitinib treatment\",\"authors\":\"Diego Marquez-Medina , Sanjay Popat\",\"doi\":\"10.1016/j.ctrc.2015.06.003\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Advanced non-small cell lung cancer (NSCLC), the most lethal malignancy worldwide, obtains a small long-term benefit from chemotherapy. However, 16% of Caucasian patients presenting sensitizing mutations in the epidermal growth factor receptor have a high sensitivity to the tyrosine kinase inhibitor gefitinib. Gefitinib is a safe drug, with mild diarrhea, emesis, or skin rash the most common toxicities. However, rare adverse events such as <em>pneumatosis intestinalis</em> have been communicated. We first report a very rare case of emphysematous cystitis in a female patient with <em>EGFR</em>-mutant lung adenocarcinoma while on gefitinib treatment, taken advance to review risk factors for this infectious complication.</p></div>\",\"PeriodicalId\":90461,\"journal\":{\"name\":\"Cancer treatment communications\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2015-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1016/j.ctrc.2015.06.003\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer treatment communications\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2213089615300037\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer treatment communications","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2213089615300037","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Steroid-related emphysematous cystitis in an EGFR-mutant patient with lung adenocarcinoma while on gefitinib treatment
Advanced non-small cell lung cancer (NSCLC), the most lethal malignancy worldwide, obtains a small long-term benefit from chemotherapy. However, 16% of Caucasian patients presenting sensitizing mutations in the epidermal growth factor receptor have a high sensitivity to the tyrosine kinase inhibitor gefitinib. Gefitinib is a safe drug, with mild diarrhea, emesis, or skin rash the most common toxicities. However, rare adverse events such as pneumatosis intestinalis have been communicated. We first report a very rare case of emphysematous cystitis in a female patient with EGFR-mutant lung adenocarcinoma while on gefitinib treatment, taken advance to review risk factors for this infectious complication.